search
Back to results

ICSI Versus Conventional IVF in Non-male Factor Couples

Primary Purpose

Infertility

Status
Completed
Phase
Not Applicable
Locations
Vietnam
Study Type
Interventional
Intervention
ICSI
IVF
Sponsored by
Mỹ Đức Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring ICSI, Conventional IVF, Non-male factor

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Having ≤ 2 IVF/ICSI cycles
  • Total sperm count and motility are normal (WHO, 2010)
  • Antagonist protocol
  • Agree to have ≤ 2 embryos transferred
  • Not participating in another IVF study at the same time

Exclusion Criteria:

  • In-vitro maturation (IVM) cycles
  • Using frozen semen
  • Poor fertilization in previous cycle (≤ 25%)

Sites / Locations

  • Dang Q Vinh

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Intracytoplasmic Sperm Injection (ICSI)

In Vitro Fertilization (IVF)

Arm Description

All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen.

All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen.

Outcomes

Primary Outcome Measures

Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle.
Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count). For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.

Secondary Outcome Measures

Fertilization rate per oocyte inseminated/injected
Fertilization is defined as the appearance of 2 PN
Fertilization rate per oocyte retrieved
Fertilization is defined as the appearance of 2 PN
Abnormal fertilization rate
Abnormal fertilization is defined as the appearance of 1PN or ≥3 PN
Total fertilization failure rate
Total fertilization is defined as the absence of any zygotes with 2PN
Number of embryos on day 3
Number of embryos on day 3
Number of good quality embryo on day 3
Numbers of embryos on day 3 with good quality
Number of embryo freezing on day 3
Number of embryos freezing on day 3
Positive pregnancy test
Positive pregnancy test is defined as a serum human chorionic gonadotropin level greater than 25 mIU/mL after the completion of the first transfer
Clinical pregnancy
Clinical pregnancy is defined as the presence of at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity, after the completion of the first transfer
Implantation rate
Implantation rate is defined as the number of gestational sacs per number of embryos transferred after the completion of the first transfer
Ongoing pregnancy
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer
Cumulative ongoing pregnancy
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after transfer of all embryos from the started treatment cycle.
Ongoing pregnancy resulting in live birth obtained from all embryos from the first started treatment cycle
Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).
Time from randomization to ongoing pregnancy
Time from randomization to ongoing pregnancy after the completion of the first transfer
Ovarian hyperstimulation syndrome (OHSS)
Symptoms of OHSS
Ectopic pregnancy
A pregnancy in which implantation takes place outside the uterine cavity after completion of the first transfer
Ectopic pregnancy
A pregnancy in which implantation takes place outside the uterine cavity after transfer of all embryos from the started treatment cycle.
Miscarriage
The loss of a clinical pregnancy at 24 weeks of gestation after the completion of the first transfer
Miscarriage
The loss of a clinical pregnancy at 24 weeks of gestation after the completion transfer of all embryos from the started treatment cycle
Multiple pregnancy
Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion of the first transfer
Multiple pregnancy
Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion transfer of all embryos from the started treatment cycle
Multiple delivery
Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion of the first transfer
Multiple delivery
Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion transfer of all embryos from the started treatment cycle
Gestational diabetes mellitus
Development of diabetes during pregnancy
Gestational diabetes mellitus
Development of diabetes during pregnancy
Hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)
Hypertensive disorders of pregnancy
Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)
Antepartum haemorrhage
Including placenta previa, placenta accreta and unexplained
Antepartum haemorrhage
Including placenta previa, placenta accreta and unexplained
Gestational age at delivery
Gestational age at delivery
Gestational age at delivery
Gestational age at delivery
Preterm delivery
Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation
Preterm delivery
Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation
Spontaneous preterm birth
Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks
Spontaneous preterm birth
Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks
Iatrogenic preterm birth
Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks
Iatrogenic preterm birth
Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks
Birth weight
Weight of newborn
Birth weight
Weight of newborn
Low birth weight
Low birth weight is defined as <2500 gm
Low birth weight
Low birth weight is defined as <2500 gm
Very low birth weight
Very low birth weight is defined as <1500 gm
Very low birth weight
Very low birth weight is defined as <1500 gm
High birth weight
High birth weight is defined as >4000 gm
High birth weight
High birth weight is defined as >4000 gm
Very high birth weight
Very high birth weight is defined as >4500 gm
Very high birth weight
Very high birth weight is defined as >4500 gm
Large for gestational age
Large for gestational age is defined as birth weight >90th percentile
Large for gestational age
Large for gestational age is defined as birth weight >90th percentile
Small for gestational age
Small for gestational age is defined as birth weight <10th percentile
Small for gestational age
Small for gestational age is defined as birth weight <10th percentile
Congenital anomaly diagnosed at birth
Any congenital anomaly will be included
Congenital anomaly diagnosed at birth
Any congenital anomaly will be included
Admission to NICU
The admittance of the newborn to NICU
Admission to NICU
The admittance of the newborn to NICU
Genetic and epigenetic analysis of newborn
Maternal whole blood; newborn's materials including cord blood, neonatal buccal smear, and placental tissue will be collected. Data will be collected for a supplementary analysis and will be reported in a separated paper.
Cost-effectiveness
Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.

Full Information

First Posted
February 2, 2018
Last Updated
October 7, 2020
Sponsor
Mỹ Đức Hospital
Collaborators
An Sinh Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03428919
Brief Title
ICSI Versus Conventional IVF in Non-male Factor Couples
Official Title
The Effectiveness of Intracytoplasmic Sperm Injection Versus Conventional in Vitro Fertilization in Couples With Non-male Factor Infertility: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
March 16, 2018 (Actual)
Primary Completion Date
August 1, 2020 (Actual)
Study Completion Date
August 12, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mỹ Đức Hospital
Collaborators
An Sinh Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Conventionally, ICSI was initially developed and has been shown to be an effective treatment for male factor infertility. It is increasingly being used for patients without a male factor diagnosis, despite the lack of clinical evidence to support its use. Moreover, ICSI is an invasive and expensive procedure. This multi-center, randomized, controlled, parallel-group trial will be conducted to compare the effectiveness of ICSI versus conventional IVF in infertile couples scheduled for IVF treatment, in whom the male partner has normal sperm.
Detailed Description
All patients undergoing IVF/ICSI will be treated with a GnRH antagonist protocol. Recombinant FSH (Puregon, MSD) will be given on day 2 or day 3 of menstrual cycle for 5 days. The starting dose is individualized for each patient based on the following criteria: AMH <0.7 ng/mL, dose 300 IU/day; AMH 0.7-2.1 ng/mL, dose 200 IU/day; AMH >2.1 ng/mL, dose 150 IU/day. After that, investigators can titrate the dose based on their clinical judgment. Follicular development will be monitored by ultrasound scanning and measurement of estradiol and progesterone levels, starting on day 5 of stimulation. Scanning and hormonal measurement will be repeated every 2 to 3 days, depending on the size of follicles. An antagonist is routinely used on day 5 until the day of triggering. Criteria for triggering, by hCG (Ovitrelle 250 mg, Merck, Germany) will be the presence of at least three leading follicles of 17 mm. In women with excessive follicular response (≥15 follicles ≥12 mm), 0,2 mg Triptorelin (Diphereline, Ipsen Beaufour, France) will be used when there are at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Randomization and allocation of participants to study groups will be performed on the day of egg pick up, after having obtained the semen from the husband. Eligible participants that have provided informed consent will be randomised to either ICSI or conventional IVF. In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated. In conventional IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium. In both groups, fertilization check will be performed under inverted microscope at period of 16-18 hours after insemination. On day 3, embryo evaluation will be performed at fixed time point 66±2 hours after fertilization, using the Istanbul consensus. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen. Luteal-phase support will be done with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800mg/day (Cyclogest 400mg) until 7th week of gestation. If there are contra-indications for fresh embryo transfer, a freeze-all strategy will be applied, using Cryotech technique. Indications for freeze-all include: risk of ovarian hyperstimulation syndrome (OHSS), premature progesterone rise (≥1.5 ng/ml), thin endometrium (<7 mm), fluid in cavity on day of embryo transfer, endometrial polyp, hydrosalpinx that have not removed before oocyte retrieval. In the next cycle, endometrium will be prepared by using estradiol (Valiera 2 mg, 8 mg/day) orally, starting from day 2-3 of menstrual cycle. When the endometrium thickness reaches 8 mm or more, patients will start using progesterone vaginally (Cyclogest 400 mg, 800 mg/day). Embryo transfer will be performed 3 days after using progesterone. On the day of embryo transfer, embryos will be thawed. In the frozen/thawed cycle, the best embryos will be utilized first, as in fresh transfer. Two hours after thawing, a maximum of 2 surviving embryos will be transferred into the uterus under ultrasound guidance. Luteal phase support will be provided with estradiol (Valiera 2mg) 8mg/day and vaginal progesterone 800 mg/day (Cyclogest 400 mg) until the seventh week of gestation. In both groups, clinicians who perform embryo transfer, either fresh or frozen cycles, will be blinded to the intervention. A serum hCG will be measured 2 weeks after embryo transferred, and if positive, an ultrasound scan of the uterus will be performed at gestational weeks 7 and 12. At 11 - 12 weeks of gestation, participants will be referred to the Outpatient clininc, O&G Department, My Duc hospital or An Sinh hospital for prenatal care until giving birth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
ICSI, Conventional IVF, Non-male factor

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1064 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intracytoplasmic Sperm Injection (ICSI)
Arm Type
Active Comparator
Arm Description
All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen.
Arm Title
In Vitro Fertilization (IVF)
Arm Type
Active Comparator
Arm Description
All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering. Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium. Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen.
Intervention Type
Procedure
Intervention Name(s)
ICSI
Intervention Description
In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
Intervention Type
Procedure
Intervention Name(s)
IVF
Intervention Description
In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
Primary Outcome Measure Information:
Title
Ongoing pregnancy resulting in live birth after the first embryo transfer of the started treatment cycle.
Description
Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count). For the timing of this occur, ongoing pregnancy will be used, conditional on the fact that this ongoing pregnancy results in live birth.
Time Frame
At 12 weeks of gestation
Secondary Outcome Measure Information:
Title
Fertilization rate per oocyte inseminated/injected
Description
Fertilization is defined as the appearance of 2 PN
Time Frame
At 16-18 hours after injected or 17-19 hours after inseminated
Title
Fertilization rate per oocyte retrieved
Description
Fertilization is defined as the appearance of 2 PN
Time Frame
At 16-18 hours after injected or 17-19 hours after inseminated
Title
Abnormal fertilization rate
Description
Abnormal fertilization is defined as the appearance of 1PN or ≥3 PN
Time Frame
At 16-18 hours after injected or 17-19 hours after inseminated
Title
Total fertilization failure rate
Description
Total fertilization is defined as the absence of any zygotes with 2PN
Time Frame
At 16-18 hours after injected or 17-19 hours after inseminated
Title
Number of embryos on day 3
Description
Number of embryos on day 3
Time Frame
3 days after oocytes pick-up day in IVF/ICSI
Title
Number of good quality embryo on day 3
Description
Numbers of embryos on day 3 with good quality
Time Frame
3 days after oocytes pick-up day in IVF/ICSI
Title
Number of embryo freezing on day 3
Description
Number of embryos freezing on day 3
Time Frame
3 days after oocytes pick-up day in IVF/ICSI
Title
Positive pregnancy test
Description
Positive pregnancy test is defined as a serum human chorionic gonadotropin level greater than 25 mIU/mL after the completion of the first transfer
Time Frame
14 days after embryo transfer
Title
Clinical pregnancy
Description
Clinical pregnancy is defined as the presence of at least one gestational sac on ultrasound at 7 weeks' gestation with the detection of heart beat activity, after the completion of the first transfer
Time Frame
At 7 weeks' gestation
Title
Implantation rate
Description
Implantation rate is defined as the number of gestational sacs per number of embryos transferred after the completion of the first transfer
Time Frame
At 3 weeks after embryo transferred
Title
Ongoing pregnancy
Description
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after the completion of the first transfer
Time Frame
At 12 weeks' gestation
Title
Cumulative ongoing pregnancy
Description
Ongoing pregnancy is defined as pregnancy with detectable heart rate at 12 weeks' gestation or beyond, after transfer of all embryos from the started treatment cycle.
Time Frame
At 12 weeks' gestation at 12 months after randomization. After 12 months, most patients doing IVF have finished all their frozen embryos; therefore, we consider this time point for analyzing the cumulative ongoing pregnancy rate.
Title
Ongoing pregnancy resulting in live birth obtained from all embryos from the first started treatment cycle
Description
Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).
Time Frame
12 weeks of gestation at 12 months after randomization
Title
Time from randomization to ongoing pregnancy
Description
Time from randomization to ongoing pregnancy after the completion of the first transfer
Time Frame
12 weeks of gestation after the completion of first transfer
Title
Ovarian hyperstimulation syndrome (OHSS)
Description
Symptoms of OHSS
Time Frame
At 10 days after hCG injection and 14 days after embryo transfer
Title
Ectopic pregnancy
Description
A pregnancy in which implantation takes place outside the uterine cavity after completion of the first transfer
Time Frame
At 12 weeks of gestation after the completion of the first transfer
Title
Ectopic pregnancy
Description
A pregnancy in which implantation takes place outside the uterine cavity after transfer of all embryos from the started treatment cycle.
Time Frame
At 12 weeks of gestation at 12 months after randomization.
Title
Miscarriage
Description
The loss of a clinical pregnancy at 24 weeks of gestation after the completion of the first transfer
Time Frame
At 24 weeks of gestation after the completion of the first transfer
Title
Miscarriage
Description
The loss of a clinical pregnancy at 24 weeks of gestation after the completion transfer of all embryos from the started treatment cycle
Time Frame
At 24 weeks of gestation at 12 months after the randomization.
Title
Multiple pregnancy
Description
Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion of the first transfer
Time Frame
7 weeks' gestation after the completion of the first transfer
Title
Multiple pregnancy
Description
Multiple pregnancy is explained as two or more gestational sacs or positive heart beats by transvaginal sonography, after the completion transfer of all embryos from the started treatment cycle
Time Frame
7 weeks' gestation at 12 months after randomization
Title
Multiple delivery
Description
Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion of the first transfer
Time Frame
At birth, after the completion of the first transfer
Title
Multiple delivery
Description
Multiple delivery is defined as birth of more than one baby beyond 24 weeks, after the completion transfer of all embryos from the started treatment cycle
Time Frame
At birth at 12 months after randomization
Title
Gestational diabetes mellitus
Description
Development of diabetes during pregnancy
Time Frame
At 24 weeks of gestation after the completion of the first transfer
Title
Gestational diabetes mellitus
Description
Development of diabetes during pregnancy
Time Frame
At 24 weeks of gestation at 12 months after randomization
Title
Hypertensive disorders of pregnancy
Description
Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)
Time Frame
From 20 weeks of gestation up to at birth after the completion of the first transfer
Title
Hypertensive disorders of pregnancy
Description
Hypertensive disorders of pregnancy will include pregnancy induced hypertension (PIH); pre-eclampsia (PET) and eclampsia)
Time Frame
From 20 weeks of gestation up to at birth at 12 months after randomization
Title
Antepartum haemorrhage
Description
Including placenta previa, placenta accreta and unexplained
Time Frame
From 20 weeks of gestation up to at birth, after the completion of the first transfer
Title
Antepartum haemorrhage
Description
Including placenta previa, placenta accreta and unexplained
Time Frame
From 20 weeks of gestation up to at birth, at 12 months after randomization
Title
Gestational age at delivery
Description
Gestational age at delivery
Time Frame
At birth, after the completion of the first transfer
Title
Gestational age at delivery
Description
Gestational age at delivery
Time Frame
At birth, at 12 months after randomization
Title
Preterm delivery
Description
Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation
Time Frame
At birth, after the completion of the first transfer
Title
Preterm delivery
Description
Preterm delivery is defined as any delivery at <24, <28, <32, <37 completed weeks' gestation
Time Frame
At birth, at 12 months after randomization
Title
Spontaneous preterm birth
Description
Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks
Time Frame
At birth, after the completion of the first transfer
Title
Spontaneous preterm birth
Description
Spontaneous preterm birth is defined as delivery spontaneously at <24, <28, <32, <37 completed weeks
Time Frame
At birth, at 12 months after randomization
Title
Iatrogenic preterm birth
Description
Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks
Time Frame
At birth, after the completion of the first transfer
Title
Iatrogenic preterm birth
Description
Iatrogenic preterm birth is defined as delivery non-spontaneously at <24, <28, <32, <37 completed weeks
Time Frame
At birth, at 12 months after randomization
Title
Birth weight
Description
Weight of newborn
Time Frame
At birth, after the completion of the first transfer
Title
Birth weight
Description
Weight of newborn
Time Frame
At birth, at 12 months after randomization
Title
Low birth weight
Description
Low birth weight is defined as <2500 gm
Time Frame
At birth, after the completion of the first transfer
Title
Low birth weight
Description
Low birth weight is defined as <2500 gm
Time Frame
At birth, at 12 months after randomization
Title
Very low birth weight
Description
Very low birth weight is defined as <1500 gm
Time Frame
At birth, after the completion of the first transfer
Title
Very low birth weight
Description
Very low birth weight is defined as <1500 gm
Time Frame
At birth, at 12 months after randomization
Title
High birth weight
Description
High birth weight is defined as >4000 gm
Time Frame
At birth, after the completion of the first transfer
Title
High birth weight
Description
High birth weight is defined as >4000 gm
Time Frame
At birth, at 12 months after randomization
Title
Very high birth weight
Description
Very high birth weight is defined as >4500 gm
Time Frame
At birth, after the completion of the first transfer
Title
Very high birth weight
Description
Very high birth weight is defined as >4500 gm
Time Frame
At birth, at 12 months after randomization
Title
Large for gestational age
Description
Large for gestational age is defined as birth weight >90th percentile
Time Frame
At birth, after the completion of the first transfer
Title
Large for gestational age
Description
Large for gestational age is defined as birth weight >90th percentile
Time Frame
At birth, at 12 months after randomization
Title
Small for gestational age
Description
Small for gestational age is defined as birth weight <10th percentile
Time Frame
At birth, after the completion of the first transfer
Title
Small for gestational age
Description
Small for gestational age is defined as birth weight <10th percentile
Time Frame
At birth, at 12 months after randomization
Title
Congenital anomaly diagnosed at birth
Description
Any congenital anomaly will be included
Time Frame
At birth, after the completion of the first transfer
Title
Congenital anomaly diagnosed at birth
Description
Any congenital anomaly will be included
Time Frame
At birth, at 12 months after randomization
Title
Admission to NICU
Description
The admittance of the newborn to NICU
Time Frame
7 days after delivery after the completion of the first transfer
Title
Admission to NICU
Description
The admittance of the newborn to NICU
Time Frame
7 days after delivery, at 12 months after randomization
Title
Genetic and epigenetic analysis of newborn
Description
Maternal whole blood; newborn's materials including cord blood, neonatal buccal smear, and placental tissue will be collected. Data will be collected for a supplementary analysis and will be reported in a separated paper.
Time Frame
1 day (Prior to the initiation of IVF/IVM) and 1 day ( at the time of delivery)
Title
Cost-effectiveness
Description
Including direct and indirect costs; costs related to complications treatment. Cost data will be collected for a supplementary analysis and will be reported in a separated paper.
Time Frame
Two year after randomization

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Having ≤ 2 IVF/ICSI cycles Total sperm count and motility are normal (WHO, 2010) Antagonist protocol Agree to have ≤ 2 embryos transferred Not participating in another IVF study at the same time Exclusion Criteria: In-vitro maturation (IVM) cycles Using frozen semen Poor fertilization in previous cycle (≤ 25%)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lan N Vuong, PhD
Organizational Affiliation
University of Medicine and Pharmacy at Ho Chi Minh City
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dang Q Vinh
City
Hochiminh city
Country
Vietnam

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33894833
Citation
Dang VQ, Vuong LN, Luu TM, Pham TD, Ho TM, Ha AN, Truong BT, Phan AK, Nguyen DP, Pham TN, Pham QT, Wang R, Norman RJ, Mol BW. Intracytoplasmic sperm injection versus conventional in-vitro fertilisation in couples with infertility in whom the male partner has normal total sperm count and motility: an open-label, randomised controlled trial. Lancet. 2021 Apr 24;397(10284):1554-1563. doi: 10.1016/S0140-6736(21)00535-3.
Results Reference
derived
PubMed Identifier
30937394
Citation
Dang VQ, Vuong LN, Ho TM, Ha AN, Nguyen QN, Truong BT, Pham QT, Wang R, Norman RJ, Mol BW. The effectiveness of ICSI versus conventional IVF in couples with non-male factor infertility: study protocol for a randomised controlled trial. Hum Reprod Open. 2019 Mar 27;2019(2):hoz006. doi: 10.1093/hropen/hoz006. eCollection 2019.
Results Reference
derived

Learn more about this trial

ICSI Versus Conventional IVF in Non-male Factor Couples

We'll reach out to this number within 24 hrs